SEC Comment Letter 0000000000-24-011986 to Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals Ltd.
Date: Oct. 28, 2024 · CIK: 0001595353 · Accession: 0000000000-24-011986
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282753
Letter
October 28, 2024 Allen Baharaff President and Chief Executive Officer Galmed Pharmaceuticals Ltd. c/o Meitar Law Offices Abba Hillel Silver Rd. Ramat Gan 5250608 Israel Re:Galmed Pharmaceuticals Ltd. Registration Statement on Form F-1 Filed October 21, 2024 File No. 333-282753 Dear Allen Baharaff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel, Esq.
Show Raw Text
October 28, 2024
Allen Baharaff
President and Chief Executive Officer
Galmed Pharmaceuticals Ltd.
c/o Meitar Law Offices
Abba Hillel Silver Rd.
Ramat Gan 5250608 Israel
Re:Galmed Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed October 21, 2024
File No. 333-282753
Dear Allen Baharaff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.